# A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

> **NCT06035497** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 85 (estimated)

## Conditions studied

- Relapsed or Refractory T-cell Lymphomas

## Interventions

- **DRUG:** BMS-986369

## Key facts

- **NCT ID:** NCT06035497
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-20
- **Primary completion:** 2027-01-30
- **Final completion:** 2030-10-10
- **Target enrollment:** 85 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06035497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06035497, "A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06035497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*